We believe that in the next 5 years, as the widespread implementation of high-throughput sequencing and in-depth investigation of the role of MET in cancer occurs, more rare mutation sites will be discovered and more target drugs will be developed to treat patients with more detailed classifications. The gene discussed is MET; the disease is cancer.